Physician profile
Cindy Loeb
NPI 1942889126
$8,572.74
in general payments reported to CMS, 2019-2025
30 companies · $3,867 in 2025
The $3,867 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.63 · 2023: $1,952 · 2024: $2,741 · 2025: $3,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,516 · Education: $44.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,515.55 |
| Education | $44.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,409.26 | 2023-2025 | |
| Janssen Biotech, INC. | $1,037.39 | 2023-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $859.94 | 2023-2025 | Xifaxan |
| Genzyme Corporation | $542.98 | 2023-2025 | |
| Ardelyx, INC. | $511.44 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $405.71 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $377.16 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $342.49 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Phathom Pharmaceuticals, INC. | $332.99 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $290.83 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $261.52 | 2023-2025 | Ocaliva |
| Qol Medical, LLC | $248.04 | 2024-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $238.93 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $208.15 | 2024-2025 | Vegzelma, Zymfentra |
| Aimmune Therapeutics, INC. | $201.37 | 2023-2025 | Zenpep |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $193.13 | 2023-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $181.23 | 2024-2025 | Iqirvo, Bylvay |
| Fresenius Kabi USA, LLC | $141.84 | 2023-2024 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $128.55 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $120.32 | 2023-2024 | Suflave, Sutab |
| Merck Sharp & Dohme LLC | $115.38 | 2023-2024 | Dificid, Zinplava, Zerbaxa |
| Ironwood Pharmaceuticals, INC | $96.48 | 2023-2024 | Linzess |
| Gilead Sciences, INC. | $84.54 | 2025 | |
| Amgen INC. | $84.18 | 2023-2025 | Avsola, Amjevita, Uplizna |
| Evoke Pharma, INC. | $38.56 | 2023-2025 | Gimoti |
| Nestle Healthcare Nutrition INC. | $33.00 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.05 | 2023-2024 | Cyltezo |
| Ucb, INC. | $20.96 | 2023 | Cimzia |
| Alnylam Pharmaceuticals INC. | $17.94 | 2023 | Givlaari |
| Ferring Pharmaceuticals INC. | $16.38 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Loeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.